Anifrolumab

Therapeutic indications

Anifrolumab is indicated for:

Moderate to severe, active autoantibody-positive systemic lupus erythematosus (SLE)

Population group: both men and women, only adults (18 years old or older)

Anifrolumab is indicated as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (SLE), despite standard therapy.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines